Defunct Company
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
102
NCT02500680
The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)
Phase: Phase 1
Role: Collaborator
Start: Jul 31, 2015
Completion: Dec 31, 2020